Insight, China's Pharmaceutical Industry

Company Deals

Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...

Company Drug

Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE

Fineline Cube Dec 30, 2022

China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

BrightGene Receives NMPA Approval for BGM0504 Clinical Trial

Fineline Cube Dec 30, 2022

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...

Drug

Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study

Fineline Cube Dec 30, 2022

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...

Company Drug

AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment

Fineline Cube Dec 30, 2022

UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...

Company Deals

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

Fineline Cube Dec 30, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...

Company Deals

Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing

Fineline Cube Dec 30, 2022

Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has...

Company

Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline

Fineline Cube Dec 30, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half...

Company Drug

Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial

Fineline Cube Dec 29, 2022

The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...

Company Drug Legal / IP

Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound

Fineline Cube Dec 29, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...

Company Drug

Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile

Fineline Cube Dec 29, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...

Company Drug

Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong

Fineline Cube Dec 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA

Fineline Cube Dec 29, 2022

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

Fineline Cube Dec 29, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...

Company Drug

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fineline Cube Dec 29, 2022

China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...

Company Deals

Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round

Fineline Cube Dec 29, 2022

China-based household healthcare and nursing brand Fortune Care reportedly raised over RMB 100 million (USD...

Company Deals

Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital

Fineline Cube Dec 29, 2022

China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...

Company

WuXi Biologics Receives First GMP Certificate from Ireland HPRA

Fineline Cube Dec 28, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...

R&D

CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity

Fineline Cube Dec 28, 2022

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA

Fineline Cube Dec 28, 2022

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for...

Insight, China's Pharmaceutical Industry

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech

Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE

BrightGene Receives NMPA Approval for BGM0504 Clinical Trial

Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study

AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing

Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline

Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial

Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound

Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile

Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong

Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round

Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital

WuXi Biologics Receives First GMP Certificate from Ireland HPRA

CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity

SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories